First Trust Nasdaq Pharmaceuticals ETF (FTXH) Short Interest Ratio & Short Volume

Short interest is the volume of First Trust Nasdaq Pharmaceuticals ETF shares that have been sold short but have not yet been closed out or covered. As of April 15th, investors have sold 300 shares of FTXH short. 0.05% of First Trust Nasdaq Pharmaceuticals ETF's shares are currently sold short. Learn More on First Trust Nasdaq Pharmaceuticals ETF's current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.05% of First Trust Nasdaq Pharmaceuticals ETF's floating shares are currently sold short.

First Trust Nasdaq Pharmaceuticals ETF saw a drop in short interest in April. As of April 15th, there was short interest totaling 300 shares, a drop of 57.1% from the previous total of 700 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

0.05% of First Trust Nasdaq Pharmaceuticals ETF's shares are currently sold short. Here is how the short interest of companies compare to First Trust Nasdaq Pharmaceuticals ETF: JPMorgan Healthcare Leaders ETF (0.07%), ProShares UltraShort Nasdaq Biotechnology (4.44%), Invesco Nasdaq Biotechnology ETF (0.14%), ProShares Ultra Nasdaq Biotechnology (1.22%), Invesco Dorsey Wright Healthcare Momentum ETF (0.21%), VanEck Biotech ETF (0.49%), VanEck Pharmaceutical ETF (41.19%), and iShares Biotechnology ETF (23.58%).

As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($21.71 billion), iShares 20+ Year Treasury Bond ETF ($9.48 billion), Strategy Incorporated ($8.92 billion), Charter Communications, Inc. ($3.86 billion), Apollo Global Management, Inc. ($3.86 billion), Capital One Financial Co. ($3.72 billion), Super Micro Computer, Inc. ($3.47 billion), AppLovin Co. ($2.64 billion), VanEck Semiconductor ETF ($2.46 billion), and The Kroger Co. ($2.33 billion). View all of the most shorted stocks.

Short selling FTXH is an investing strategy that aims to generate trading profit from First Trust Nasdaq Pharmaceuticals ETF as its price is falling. FTXH shares are trading up $0.10 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for First Trust Nasdaq Pharmaceuticals ETF occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of FTXH, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including FTXH, twice per month. The most recent reporting period available is April, 15 2025.